|
|
Article: New Preclinical Discovery Shows GlycoGenesys' Cancer Drug Candidate GCS-100 Inhibits AKT1 (Promoter of Cancer Cell Survival and Drug Resistance) in B-Cell Malignancies.
- Article from:
- Business Wire
- Article date:
- September 19, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOSTON -- Data Presented At The XI International Work Shop on Chronic Lymphocytic Leukemia
GlycoGenesys, Inc., (NASDAQ: GLGS), a biotechnology company, today announced that Dr. Finbarr Cotter, Professor, Barts and The London School of Medicine UK, revealed new findings about the Company's cancer drug candidate GCS-100 over the weekend at the prestigious XI International Work Shop on Chronic Lymphocytic Leukemia in New York City. The poster presentation and a corresponding abstract from the conference were entitled "GCS-100, A Selective Galectin-3 Mediated CLL Therapy Induces Angiogenic and AKT1 Inhibition With Caspase-9 Activation."
AKT1:
The ...